Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
about
Inflammatory bowel diseases: Current problems and future tasks.Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentA study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel diseasePsoriasiform Eruption and Worsening of Pustulosis Palmoplantaris After Treatment with Two Anti-TNF-α Inhibitors, Followed by Successful Treatment with Ustekinumab.Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.The safety of treatment options for pediatric Crohn's disease.Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases.The safety of vedolizumab for ulcerative colitis and Crohn's disease.Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
P2860
Q34047672-2002E979-9893-4F19-AF2F-6EDF19D0AF74Q34073191-AB130743-BA53-4E71-B8EB-713F8A47D902Q35100143-312CC530-7EA1-4A86-96C7-A68B1E635153Q35973766-05EC83A1-D601-4AAB-92D6-CFFF2A5F423DQ37432268-4747153E-E7A6-4AEA-A4FE-397567EAEADAQ38315640-D14D493D-05CB-4F81-A283-01E65D12D3F9Q38883237-A0158075-9FD7-4458-87F5-009E828AE3D5Q39453926-2356F7A4-5074-4CC7-B445-69267FD586B3Q39985219-9FDAF15E-93D8-44A2-869E-0C3494F8C7A0Q40791552-B173DCD8-AA23-4E4F-A9A5-108F74398E9AQ40792685-FE2A8182-9D9E-4DC8-931E-A1307D7CF4BAQ49970991-911AC487-4290-494D-80D5-D70B6A19044F
P2860
Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Tumor necrosis factor α antago ...... dverse event reporting system.
@en
Tumor necrosis factor α antago ...... dverse event reporting system.
@nl
type
label
Tumor necrosis factor α antago ...... dverse event reporting system.
@en
Tumor necrosis factor α antago ...... dverse event reporting system.
@nl
prefLabel
Tumor necrosis factor α antago ...... dverse event reporting system.
@en
Tumor necrosis factor α antago ...... dverse event reporting system.
@nl
P2093
P2860
P1476
Tumor necrosis factor α antago ...... dverse event reporting system.
@en
P2093
Arthur M Barrie
Jason M Swoger
Julia B Greer
Kevin E Kip
Lisa M Grandinetti
Miguel D Regueiro
P2860
P304
P356
10.1097/MIB.0B013E31828075BD
P577
2013-05-01T00:00:00Z